Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

JW Therapeutics Partners with 2seventy bio to Develop T Cell Immunotherapies

publication date: Oct 27, 2022

Shanghai JW Therapeutics will partner with Boston’s 2seventy bio to use 2seventy’s cell therapy platform to develop T cell-based immunotherapies for Greater China. The collaboration will focus initially on 2seventy bio’s MAGE-A4 TCR program in solid tumors. JW will be responsible for development, manufacturing, and commercialization within China. 2seventy bio will receive milestones and royalty payments on revenues in China, and 2seventy may use JW’s clinical data to support ex-China development. Financial details of the agreement were not disclosed. More details....

Stock Symbols: (HK: 2126) (NSDQ: TSVT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital